The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 57 | — | 20.1x | Near average | |
Growth | 46 | 26.6% | 5.6% | Near average | |
Quality | 48 | -3.8% | 7.6% | Near average | |
Safety | 52 | 2.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Supernus Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Supernus Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
SUPN stock shows remarkable stability in analyst estimates over the past 30 days, with the average price target holding steady at $60, representing a premium of approximately 24% over the current price ($48.21). This consistency reflects cautious optimism from a limited number of analysts (only two analysts), with a decrease in opinion dispersion as the range fluctuates between $55 and $65, indicating relative agreement on the stock's fair value in the short term.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.